Compare Incyte Corporation (INCY) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Schwab US Dividend Equity ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Schwab US Dividend Equity ETF trades at $33.04 (market cap $110.56B). The key difference: Schwab US Dividend Equity ETF is far larger — about 4.8× Incyte Corporation's market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| INCY | SCHD | |
|---|---|---|
Market Cap | $22.85B | $110.56B |
Volume | 1,927,029 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $129.93 | $35.21 |
52-Week Low | $83.80 | $26.44 |
Typical Hold Time | 33 Days | 62 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
SCHD trades at $33.15, up 1.53% today, with a bullish technical signal despite mixed moving averages. The ETF has outperformed the S&P 500 by nearly 10 percentage points in 2026, with recent dividend growth attracting income-focused investors. Technical indicators show neutral oscillators but strong trend momentum with ADX readings above 60.
SCHD offers dividend growth potential with lower fees than competitors, though its defensive tilt may lag in growth markets. Key risks include interest rate sensitivity and methodology constraints that excluded high-performing stocks like Broadcom. The current pullback from August highs presents a potential entry point for long-term dividend investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
